Company's VP of Scientific Oversight to present AMDL's Onko-Sure(TM) in vitro diagnostic cancer test to conference attendees
TUSTIN, Calif., July 22 /PRNewswire-FirstCall/ -- AMDL Diagnostics Inc., a wholly-owned subsidiary of AMDL Inc. (NYSE Alternext US: ADL), announced today its Vice President of Scientific Oversight of AMDL Diagnostics Inc. is presenting at this year's AACC Annual Meeting and Clinical Lab Expo in Chicago, IL.
Dr. Andrea Small-Howard will introduce AMDL's non-invasive Onko-Sure(TM) in vitro (IVD) diagnostic blood test to conference attendees that include clinical laboratory professionals, physicians, research scientists, and other individuals involved with clinical chemistry and related disciplines. AMDL's Onko-Sure IVD diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers, including CRC, by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products.
With the exception of heart disease, cancer causes more deaths than any other medical condition in the world. According to the World Health Organization (WHO), cancer is rapidly becoming the leading cause of death worldwide and is expected to overtake heart disease by 2010. As the third most common cancer worldwide and the second leading cause of cancer deaths irrespective of gender in the US, CRC is one of the most commonly diagnosed of all cancers. Last year, there were approximately 151,000 new cases diagnosed in the US, roughly 51,000 deaths due to the disease*, and almost half of all patients thought to be "cured" are expected to develop a recurrence of CRC within 5 years - usually due to undetected metastases.** Frequent surveillance of diagnosed patients is recommended.
Onko-Sure is researched, developed and manufactured in AMDL Diagnostic's Tustin, California-based facilities and sold to 3rd( )party distributors, which then sell directly to CLIA-certified reference laboratories in the US as well as clinical reference labs, hospital labs and physician-operated labs in the international market. The test is approved by the US Food and Drug Administration (US FDA) for the monitoring of CRC in the US and by Health Canada as a lung cancer detection and monitoring tool. In addition the test is approved in Europe, where it has obtained the CE mark approval, and Taiwan, South Korea, India, and Vietnam as a general cancer screen.
According to AMDL Chairman and CEO Mr. Douglas MacLellan, "Since AMDL Diagnostics began commercializing its Onko-Sure IVD cancer test we've seen substantive market demand both as a CRC monitoring test and a pan tumor cancer screen.
